Articles tagged with Vascular Endothelial Growth Factor
The review article examines the relationship between anemia and retinopathy of prematurity, focusing on iron deficiency and underlying molecular mechanisms. Anemia reduces oxygen delivery to the retina, exacerbating hypoxia and promoting pathological neovascularization.
Researchers have identified a new experimental drug that can bridge the gap between patients with wet age-related macular degeneration (AMD) and existing treatments. The drug, 32-134D, decreases levels of a key protein involved in AMD, leading to improved vision outcomes.
Researchers aim to find a new treatment pathway for diabetic retinopathy by targeting the IL-6 protein. They suspect that selectively inhibiting trans-signaling while allowing cis-signaling will stop damage and restore balance in the retina.
Researchers highlight the need to develop new anti-angiogenic agents to improve cancer treatment efficacy, citing knowledge gaps in human clinical trials. The review recommends considering tumor mutations, microenvironment, and patient profiles to select optimal AAD combinations.
A multidisciplinary team created a new algorithm to provide optimal personalized treatment options for individuals with esophageal cancer. The framework uses various heterogeneous factors that facilitate the progression of the disease and demonstrated high accuracy in controlling esophageal cancer.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.
Researchers developed a low-cost anti-inflammatory hydrogel containing annexin A1 that accelerated complete skin wound healing in mice with induced type 1 diabetes. The hydrogel modulated the wound microenvironment and favored tissue regeneration, reducing inflammation and improving blood vessel formation.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
A team from Tokyo Medical and Dental University has developed a technique to improve bone regeneration over large areas in rats, using vascular endothelial growth factor (VEGF) and Runx2. The combination of these two RNAs led to better regenerative responses in bone cells than each RNA alone.
Researchers have found that stimulating a specific bile acid receptor, FXR, may help prevent retinopathy of prematurity in premature babies. By targeting this receptor, the study aims to develop earlier and more effective treatments to protect their vision.
Researchers developed an experimental drug, 32-134D, that inhibits HIF protein levels, reducing blood vessel production and leakiness in diabetic eyes. The study shows promising results in both human cell models and mice, suggesting a safer therapeutic approach for diabetic eye disease.
Researchers have found a new target and drug combination that appears to stop the destruction of vision in premature newborns. By blocking ACAT1, an enzyme that converts cholesterol into smaller pieces, scientists can prevent the formation of leaky blood vessels and inflammation in the retina.
UVA scientists have discovered a new contributor to abnormal blood vessel growth in the eye, which could lead to new treatments for macular degeneration and other vision loss conditions. The discovery identifies a key protein that determines VEGF levels, blocking it has reduced VEGF levels significantly without unwanted side effects.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers discovered PDGF cross-signaling through alternative receptors in colorectal cancer cells, enabling bypassed signaling. This finding supports anti-PDGF therapy as a combination strategy alongside VEGF and EGF targeting.
Researchers at Karolinska Institutet discovered that SARS-CoV-2 infection triggers blood vessel formation in fat tissues, leading to thermogenic metabolism and significant weight loss. Blocking this process with an antiangiogenic drug restored weight loss in mice and hamsters infected with the virus.
Researchers found that dietary saturated/trans fats, but not cholesterol, can trigger hepatic angiogenesis and lymphangiogenesis in mice, leading to the promotion of hepatic tumors. This process is driven by the JNK-HIF1α-VEGF-C axis.
Researchers explore the interactions between adipose tissues and surrounding blood vessels in connection with lipid metabolism and associated diseases. Targeting angiogenesis may provide a gateway for treating obesity, while its inhibition or promotion depends on the specific disease context.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
Researchers at Institute for Basic Science discovered Merlin's crucial role in regulating angiogenesis. By suppressing VEGFR2 internalization, Merlin prevents tip EC induction and promotes balanced sprouting angiogenesis. This study sheds light on the importance of Merlin in maintaining capillary integrity and proper angiogenesis.
Scientists found that a single 45-minute session of moderate-intensity exercise enables the growth of new blood vessels in people with type 2 diabetes. The exercise increases levels of ATP7A, a protein carried by exosomes that helps deliver essential copper to endothelial cells, promoting angiogenesis and reducing oxidative stress.
Researchers at UC Riverside have discovered that curcumin promotes vascular endothelial growth factor (VEGF) secretion, helping to grow engineered blood vessels and tissues. The study uses magnetic hydrogels coated with curcumin-coated nanoparticles, which gradually release the compound without injuring cells.
A study suggests that the powerhouse-pruning protein Drp1 plays a crucial role in generating energy for new blood vessel growth, particularly under low oxygen conditions. When oxygen levels are low, Drp1 gets modified to produce reactive oxygen species (ROS), which enables glycolysis and subsequent cell signaling.
Researchers have found that two receptors on the surface of endothelial cells come together to enable new blood vessel growth. The discovery reveals a new connection between copper metabolism and angiogenesis, highlighting CTR1 as a potential therapeutic target for conditions like ischemic heart disease.
Researchers found a unique bivalent histone-mark switch specific to critical transcription factors that induce genes essential for angiogenesis. The histone modifiers responsible for this modification are vital for postnatal angiogenesis.
Researchers found that CD146 expression is linked to retinal neovascularization in laser-induced CNV models. Anti-CD146 therapy showed promise in reducing neovascularization and improving vision outcomes.
Researchers developed a novel exosome-based treatment to deliver VEGF antibodies and suppress inflammation in ocular diseases. The therapy, rEXS-cL-aV, showed potent therapeutic efficacy in murine and nonhuman primate models.
The study identifies novel non-coding RNAs involved in regulating vascular endothelial growth factors (VEGF) expression, which are key regulators of angiogenesis. These findings may lead to new therapeutic approaches for diseases such as atherosclerosis and ischemia.
The study reveals the involvement of SARAF and Orai1 proteins in VEGF-mediated activation of endothelial cells, affecting blood vessel development. This discovery could lead to therapeutic strategies controlling angiogenesis in pathological conditions.
A novel adhesive patch platform has been developed by a research team at Pohang University of Science & Technology (POSTECH) to efficiently deliver blood vessel-forming growth factors using mussel adhesive protein. The platform demonstrated effective neovascularization in rat models for myocardial infarction and excisional wounds.
Researchers have identified a promising therapeutic combination for renal cell carcinoma, utilizing ACE2 expression analysis. The study found that higher ACE2 expression correlates with better overall survival in patients with RCC.
The use of intravitreal anti-vascular endothelial growth factors significantly increased in France during the COVID-19 pandemic, indicating a shift in treatment priorities. This surge in demand was likely driven by the pandemic's impact on eye care and the need for effective treatments.
A new study identified an adenovirus gene therapy vector carrying a VEGF isoform that can improve uterine blood flow in placental insufficiency. Reduced uterine blood flow and lack of bioavailable VEGF are major causes of severe fetal growth restriction, leading to serious neonatal morbidity and death.
A novel bypass route for coronary vessels in the heart has been discovered using the VEGF-B growth factor, which can stimulate new blood vessel growth in damaged areas. This finding opens up possibilities for treating myocardial infarction by re-activating embryonic vessel growth programs.
Researchers found that levodopa stabilized and improved vision in patients with advanced age-related macular degeneration (AMD), reducing the number of treatments necessary. The drug's ability to target the GPR143 receptor led to a decrease in retinal fluid and an improvement in visual acuity.
Researchers developed a small engineered peptide called PR1P, which protects VEGF from degradation and reduces apoptosis in both cell cultures and live mice. The study found significant increases in VEGF levels and reductions in lung damage in mouse models of emphysema.
St18 is a negative regulator of VEGF signaling, which plays a critical role in septic pathophysiology. Mice lacking St18 exhibit increased retinal vasculature and enhanced serum VEGF concentrations, highlighting the importance of St18 in regulating VEGF.
Researchers discovered a key mechanism behind eye vessel leakiness in diseases like age-related macular degeneration and diabetic retinopathy. By targeting this specific step, they hope to develop new treatments that can selectively block leak-inducing effects without harming nerve and blood-vessel cells.
Researchers at the NIH have successfully stopped tumor growth and blood vessel formation in mice by targeting enzymes that recycle phosphatidylinositol-(4,5)-bisphosphate. By blocking these enzymes, tumors were unable to replenish the molecule needed for new blood vessel growth, ultimately reducing tumor size and growth.
Researchers at Johns Hopkins Medicine discovered a new pathway contributing to degeneration of the light-sensitive tissue in the eye. A potential treatment involves blocking a protein called angiopoietin-like 4, which acts synergistically with VEGF activity.
Researchers found that anti-VEGF drugs ranibizumab and aflibercept are excreted into breast milk within days of injection, potentially suppressing VEGF levels in infants. The study provides valuable information for ophthalmologists counseling pregnant or nursing patients with retinal diseases.
A new study suggests that elevated estrogen levels in early pregnancy can lead to placenta abnormalities, but treating pregnant women with the growth factor VEGF could halt preeclampsia and preterm birth. Researchers found that VEGF treatment increased uterine artery remodeling and improved blood flow to the placenta.
A study by Yale researchers reveals a complex interplay between brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) in the rapid and long-lasting antidepressant effects of ketamine. Administering BDNF or VEGF to specific brain regions produces rapid and long-lasting antidepressant-like actions similar...
A newly developed model of central retinal vein occlusion in mice demonstrates the protective effects of adrenomedullin (ADM) and its receptor activity-modifying protein RAMP2. The study suggests that the ADM-RAMP2 system could be a novel therapeutic target for treating retinal vein occlusion, which affects millions worldwide.
A study found that inhibiting atypical protein kinase C reduces increased vessel permeability and blocks inflammation, potentially helping protect vision in patients with eye diseases. The therapy has therapeutic potential for diabetic retinopathy, uveitis, and retinal vein and artery occlusions.
Researchers identified TNF-alpha and VEGF as key cytokines in tumor vascularization. Targeting these molecules simultaneously could significantly increase the efficacy of existing cancer treatments.
A new enzyme-linked immunosorbent assay (ELISA) for bioanalysis of bevacizumab has been developed with a high sensitivity and selectivity. The assay limits detection to 1.01 ng/mL and offers an effective working dynamic range of 3.07-100 ng/mL.
Researchers at the University of Tokyo developed a blood vessel-on-a-chip technology that recreates a human blood vessel and shows how new capillaries grow from a single vessel. The technology can be used to develop drugs targeting angiogenesis, which is a key process in cancer growth.
Researchers at the University of Illinois found that cross-system signaling activity between growth factors can direct blood vessel growth and influence cancer progression, stroke recovery, and other disorders. This discovery offers a new pathway to developing effective therapies by promoting or inhibiting this signal.
A new study by Sanford Burnham Prebys Medical Discovery Institute identifies a crucial signaling pathway for angiogenesis, the growth of new blood vessels from pre-existing ones. The findings may improve current strategies to increase blood flow in ischemic tissues associated with atherosclerosis and diabetes.
The study identified a protein called ARF6, which plays a key role in the development of diabetic retinopathy. When inhibited with compound NAV-2729, vessel leakage and blood vessel overgrowth were significantly reduced in diabetic mice.
A groundbreaking study has found that injecting DNA into injured horse tendons and ligaments can cure lameness within two to three weeks. The gene therapy technology also showed no adverse side effects, with the horses returning to full health after just two months.
Researchers have developed an alginate hydrogel that can deliver angiogenic growth factors like VEGF and IGF to promote vascularization in ischemic tissues. The system increases blood flow and perfusion, improving muscle strength and tissue regeneration, with promising results in both young mice and aged rabbits.
A Georgia State University researcher is studying how to reduce tumor growth in lung cancer using a $2.3 million grant. The goal is to identify novel targets for treatment, as tumors become resistant to current therapies and promote new blood vessel formation.
Researchers identified secretogranin III as a potential therapeutic target for preventing diabetic retinopathy and retinopathy of prematurity. Inhibiting this protein may reduce vision loss in both conditions.
Researchers discovered that melatonin regulates VEGF production in the pituitary gland, controlling blood vessel growth and hormone release for seasonal fertility. This mechanism enables animals to adapt to changing environments and has implications for farming and human medicine.
Scientists have engineered the smallest CRISPR-Cas9 system to date, capable of delivering gene editing to muscles and eyes via AAV. This technology targets age-related macular degeneration (AMD) and other 'undruggable' genes, offering a promising therapeutic tool.
Scientists successfully delivered CRISPR-Cas9 to the eyes of mice with wet AMD, modifying the VEGF gene and reducing choroidal neovascularization (CNV) by 58%. This breakthrough could lead to a new therapeutic modality for non-hereditary degenerative diseases.
Researchers develop a new peptide that suppresses abnormal blood vessel growth and leakage in the eye, causing regression of established vessels. The peptide lasts longer than current treatments, potentially requiring only annual injections instead of monthly ones.
Researchers at KIT found that nerve cells dynamically regulate the density of blood vessel networks through fine modulation of sFlt1 and VEGF. This process is crucial for vascular development, particularly during early stages of embryonic growth.